---
layout: default
title: Actaea Spicata Root Aloe Copper Cupric Arsenite Fr
parent: 僅模型預測 (L5)
nav_order: 148
evidence_level: L5
indication_count: 0
---

# Actaea Spicata Root Aloe Copper Cupric Arsenite Fr
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ACTAEA SPICATA ROOT / ALOE / COPPER / ZINC (Multi-Component Formula): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This candidate is a multi-component combination product containing 10 ingredients—including botanical extracts, mineral compounds, and biological materials—consistent with a homeopathic or complex herbal formulation.
The TxGNN model **returned no predicted indications** for this candidate, and no regulatory approvals, original indications, or safety records were identified in available databases.
As a result, **no evidence-based repurposing evaluation can be completed at this time**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not identified |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; in this case, no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The queried drug string comprises 10 distinct ingredients:

- **Botanical extracts**: Actaea spicata root, Aloe, Fraxinus americana bark, Solanum dulcamara top, Urtica urens
- **Mineral/inorganic compounds**: Copper, Cupric arsenite, Zinc
- **Biological material**: Skim milk
- **Animal-derived**: Lytta vesicatoria (cantharidin-containing Spanish fly)

This combination is characteristic of a **homeopathic compound formulation**. TxGNN operates on single active pharmaceutical ingredients (APIs) mapped to DrugBank IDs via the knowledge graph. Because:

1. No DrugBank ID could be assigned to this multi-ingredient string
2. No individual ingredient was resolved as the primary active compound
3. No original indication was available to anchor the repurposing search

…the model could not generate any disease predictions. This is a **pipeline input issue**, not a signal that the formula lacks biological activity.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate cannot be evaluated for repurposing because the TxGNN pipeline requires a single mappable API with a DrugBank identifier. The submitted drug string describes a multi-component (likely homeopathic) formulation that is not supported by the current pipeline architecture.

**To proceed, the following is needed:**

- **Decompose the formulation**: Identify the single API or primary active ingredient intended for repurposing evaluation; submit each ingredient as a separate candidate if appropriate
- **Confirm product category**: Verify whether this product is registered as a homeopathic medicine, dietary supplement, or conventional drug in any jurisdiction—this determines which regulatory pathway and evidence standard applies
- **Resolve DrugBank mapping**: At minimum, Aloe vera, Zinc, or Copper may have individual DrugBank entries that could be queried separately
- **Clarify clinical intent**: Determine which ingredient (if any) is the therapeutic target for the new indication being explored
- **Obtain safety documentation**: Cupric arsenite is an arsenic-containing compound; TFDA package insert or equivalent regulatory safety data must be obtained before any clinical evaluation proceeds
- **Re-submit as individual APIs**: Once decomposed, each mappable ingredient should be run through the TxGNN pipeline independently

> ⚠️ **Note**: Cupric arsenite (copper(II) arsenite) contains inorganic arsenic. Any downstream clinical repurposing study involving this ingredient will require enhanced toxicological review and regulatory pre-consultation regardless of TxGNN prediction outcomes.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

